EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials

Anurag Jha, Nirmal Paudel iD, Khawaja Arham Jawaid, Muhammad Haad Munir Chaudhry, Zain Ali, Farhan Javaid, Shazia Sharif, Ayesha Asghar, Muhammad Saad, Muhammad Nabeel Saddique

Annals of Pharmacotherapy · 2026-12 · 60 (12) · 1156-1173

DOI: 10.1177/10600280261429462 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 27.03.2026. Verfasst von Anurag Jha und 9 weiteren Autor:innen. Beteiligte Einrichtung: King Edward Medical University, Lahore, Pakistan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Etrasimod is an oral sphingosine-1-phosphate receptor modulator evaluated for induction and maintenance therapy in moderately to severely active ulcerative colitis (UC). This meta-analysis aimed to assess the efficacy and safety of etrasimod in adults with active UC.

Objectives

To assess the efficacy and safety of etrasimod as induction and maintenance therapy in adults with moderately to severely active UC.

Methods

A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing etrasimod with placebo in adults (≥18 years) with moderately to severely active UC was conducted by searching PubMed, Embase, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov through November 2025. Dichotomous outcomes were pooled as risk ratios (RRs) with 95% confidence intervals (CIs) using random-effects models; heterogeneity was assessed with I 2 and χ 2 statistics. Analyses were performed with RevMan 5.4.

Results

Four RCTs, including 1239 patients (etrasimod = 826; placebo = 413) were analyzed. At 12 weeks, etrasimod significantly improved clinical remission (RR = 2.92, 95% CI 1.71-4.98; I 2 = 57%), clinical response (RR = 1.71, 95% CI 1.46-2.02; I 2 = 19%), endoscopic improvement (RR = 1.72, 95% CI 1.30-2.27; I 2 = 36%), and mucosal healing (RR = 3.11, 95% CI 1.72-5.62; I 2 = 54%). Beyond 40 weeks, etrasimod increased clinical remission (RR = 4.28, 95% CI 2.72-6.73; I 2 = 0%), clinical response (RR = 2.20, 95% CI 1.74-2.78; I 2 = 0%), endoscopic improvement (RR = 3.51, 95% CI 2.36-5.23; I 2 = 0%), mucosal healing (RR = 6.93, 95% CI 3.61-13.33; I 2 = 0%), and steroid-free remission (RR = 4.28, 95% CI 2.72-6.73; I 2 = 0%). Any treatment-emergent adverse event was slightly higher with etrasimod (RR = 1.15, 95% CI 1.04-1.28; I 2 = 0%), while serious adverse events (RR = 0.79, 95% CI 0.39-1.61; I 2 = 38%) and discontinuations due to adverse events (RR = 2.17, 95% CI 0.54-8.67; I 2 = 50%) did not differ significantly. Conclusion and Relevance: Etrasimod is effective in inducing and maintaining clinical and endoscopic remission in moderate-to-severe UC, with an acceptable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeSphingosine 1 Phosphate Receptor ModulatorsHumansRandomized Controlled Trials as TopicRemission InductionSeverity of Illness IndexTreatment OutcomeAcetatesIndoles

Stichwörter der Autor:innen

clinical remissionendoscopic improvementetrasimodmeta-analysissphingosine-1-phosphate receptor modulatorsystematic reviewulcerative colitis

Substanzen

etrasimodSphingosine 1 Phosphate Receptor ModulatorsAcetatesIndoles

Autor:innen und Institutionen

  • King Edward Medical University, Lahore, Pakistan.
  • Nishtar Medical University, Multan, Pakistan.
  • Sharif Medical City Hospital, Lahore, Pakistan.
  • Wah Medical College, Wah Cantonment, Pakistan.
  • Lahore General Hospital, Lahore, Pakistan.
  • FMH College of Medicine and Dentistry, Lahore, Pakistan.

ORCID-Profile: Nirmal Paudel

Zitieren

APA

Jha, A., Paudel, N., Jawaid, K. A., Chaudhry, M. H. M., Ali, Z., Javaid, F., Sharif, S., Asghar, A., Saad, M., & Saddique, M. N. (2026). Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials. Annals of Pharmacotherapy, 60(12), 1156-1173. https://doi.org/10.1177/10600280261429462

Vancouver

Jha A, Paudel N, Jawaid KA, Chaudhry MHM, Ali Z, Javaid F, et al. Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials. Annals of Pharmacotherapy. 2026;60(12):1156-1173. doi:10.1177/10600280261429462

BibTeX
@article{Jha2026,
  author = {Jha, Anurag and Paudel, Nirmal and Jawaid, Khawaja Arham and Chaudhry, Muhammad Haad Munir and Ali, Zain and Javaid, Farhan and Sharif, Shazia and Asghar, Ayesha and Saad, Muhammad and Saddique, Muhammad Nabeel},
  title = {Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials},
  journal = {Annals of Pharmacotherapy},
  year = {2026},
  volume = {60},
  number = {12},
  pages = {1156--1173},
  doi = {10.1177/10600280261429462}
}
Kostenlos starten →